Anti-Human B7-H3 (Ifinatamab Biosimilar)
Catalog #500032
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500032 | 1 mg | $200.00 | ||
| 500032 | 5 mg | $600.00 | ||
| 500032 | 20 mg | $1,250.00 |
Product Details
Ifinatamab is a biosimilar monoclonal antibody targeting B7-H3 (also known as CD276), a protein involved in immune regulation. This biosimilar is used primarily for research purposes and is designed to investigate its potential therapeutic applications in cancer immunotherapy. Ifinatamab works by binding to B7-H3, which plays a role in modulating immune responses, making it a candidate for enhancing anti-tumor immunity.
Specifications
| Clone | Ifinatamab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG1 |
| Recommended Isotype Control | Human IgG1 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 7.4 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human B7-H3 |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |